Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 30, 2015 9:52 PM ET

Biotechnology

Company Overview of Kindred Biosciences, Inc.

Company Overview

Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidate is SentiKin, an oral analgesic formulation of flupirtine to manage post-operative pain in dogs, cats, and horses. The company's other small molecule product candidates consist of KIND-010 for management of weight loss in cats; and KIND-012 for treatment of fevers in horses. It is also developing biologics products, such as KIND-510, a feline erythropoeitin for treatment of anemia in cats; KIND-502 for the treatment of ...

1555 Bayshore Highway

Suite 200

Burlingame, CA 94010

United States

Founded in 2012

43 Employees

Phone:

650-701-7901

Key Executives for Kindred Biosciences, Inc.

Co-Founder, Chief Executive Officer, President and Director
Age: 48
Total Annual Compensation: $495.5K
Co-Founder, Chief Operating Officer and Secretary
Age: 48
Total Annual Compensation: $386.9K
Chief Scientific Officer and Executive Vice President of Regulatory Affairs & Quality
Age: 64
Total Annual Compensation: $345.7K
Compensation as of Fiscal Year 2014.

Kindred Biosciences, Inc. Key Developments

Kindred Biosciences, Inc.(NasdaqCM:KIN) dropped from Russell 2000 Index

Kindred Biosciences, Inc. will be removed from Russell 2000 Index

Kindred Biosciences, Inc.(NasdaqCM:KIN) dropped from Russell 3000 Index

Kindred Biosciences, Inc. will be removed from the Russell 3000 Index.

Kindred Biosciences, Inc. Appoints Jennifer Elliott as Vice President of Legal Affairs and Intellectual Property

Kindred Biosciences, Inc. announced the appointment of Jennifer Elliott as Vice President of Legal Affairs and Intellectual Property. Dr. Elliott joins KindredBio from Genentech, where she most recently served as Associate General Counsel and Director of Patent Law.

Similar Private Companies By Industry

Company Name Region
Click Therapeutics, Inc. United States
Wilmington Pharmaceuticals, LLC United States
Twister Biotech, Inc. United States
BioSamPle Solutions LLC United States
Alastin Skincare, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Kindred Biosciences, Inc., please visit www.kindredbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.